|
|
||
|
|
||
| A | ||
|
|
Acceptance Criteria Act Active Ingredient Active Pharmaceutical Ingredient (API)4 Actual Yield Adulterated Substance Agency Analytical Methods Validation API Starting Material Aseptic |
|
| D | ||
|
|
Development Report Drug Drug Master File (DMF) Drug Product Drug (Medicinal) Product Drug Substance |
|
| E | ||
|
|
Equipment suitability Excipient Expected Yield Expiry/Expiration Date Extraneous Substance |
|
| F | ||
|
|
Fiber Final Intermediate Final Production Stages Finished Dosage Form (Drug Product) Finished Product Finished Process Materials |
|
| G | ||
|
|
Gang-printed labeling GMPs |
|
| H | ||
|
|
Homogeneous Material | |
| I | ||
|
|
Inactive Ingredient In-Process Control (also called Process Control) In-Process Control In-Process Material In-Process Testing Intermediate Intermediate Product |
|
| L | ||
|
|
Lot Lot Number |
|
| N | ||
|
|
New Active Substance New Chemical Entity New Molecular Entity Nonconforming Material Non-Fiber-Releasing Filter |
|
| O | ||
|
|
Optional Process Steps - draft definition | |
| Q | ||
|
|
Qualification Quality Quality Assurance (QA) Quality Attribute Quality Control (QC) Quality Control Instruments Quality Control Unit Quality Unit(s) Quarantine |
|
| S | ||
|
|
Secondary Reference
Standard Separate Facility Shelf Life Signed Significant Processing Step Solvent Specification Stability Standard Operating Procedures (SOPs) Starting Material Strength |
|
| T | ||
|
|
Toxic Impurity Theoretical Yield |
|
| U | ||
|
|
Unidentified Impurity | |
| V | ||
|
|
Validation Validation Protocol Vendor |
|
| W | ||
|
|
Working Standard | |
| Acceptance Criteria [1] | ||
|
|
The specifications and acceptance/rejection criteria, such
as acepptable quality level und unacceptable quality level, with an associated
sampling plan, that are necessary for making a decision to accept or reject
a lot or batch (of raw material , intermediate, packaging material, or active
pharmaceutical ingredient) or any other convenient subgroups of manufactured
units. This term can also be applied to validation. |
|
| Act [1] | ||
|
|
The Federal Food, Drug, and Cosmetic Act, as amended (21 U:S:C:
301 et seq.). |
|
| Active Ingredient | ||
|
|
||
| Active Ingredient [1,2] | ||
|
|
means any component that is intended to furnish pharmacological
activity or other direct effect in the diagnosis, cure, mitigation, treatment
or prevention of disease, or to affect the structure or any function of
the body of man or other animals. The term includes those components that
may undergo chemical change in the manufacture of the drug product and be
present in the drug product in a modified form intended to furnish the specified
activity or effect. - aktiver Bestandteil |
|
| Active Pharmaceutical Ingredient (API) | ||
|
|
Any substance that is represented for use in a drug and that,
when used in the manufacturing, processing, or packaging of a drug, becomes
an active ingredient or a finished dosage form of the drug. Such substances
are intended to furnish pharmacological activity or other direct effect
in the diagnosis, cure, mitigation, treatment or prevention of disease,
or to affect the structure and function of the body of humans or other animals.
APIs include substances manufactured by processes such as (1) chemical synthesis;
(2) fermentation; (3) recombinant DNA or other biotechnology methods; (4)
isolation/recovery from natural sources; or (5) any combination of these
processes. |
|
| Actual Yield [1] | ||
|
|
Means the quantity that is actually produced at any appropriate
phase of manufacture, processing, packaging of a particular drug product
API or intermediate. - aktuelle Ausbeute |
|
| Adulterated Substance | ||
|
|
Material which has either been contaminated with a foreign
substance or not manufactured using good manufacturing practices. This does
not contaminated to a material which simply does not meet physical or chemical
specifications. - unter Abweichung hergestellte Substanz |
|
| Agency | ||
|
|
United States Food and Drug Administration. (FDA) - Behörde |
|
| Analytical Methods Validation | ||
|
|
The process by which it is established, by laboratory studies, that the
performance characteristics of the method meet the requirement for the
intended analytical application. - Analytische Validierungsmethode |
|
| API Starting Material [2] | ||
|
|
A material used in the production of an API which is incorporated as
a significant structural fragment into the structure of the API. A starting
material may be an article of commerce, a material purchased from one
or more suppliers under contract or commercial agreement, or it may be
produced in-house. Starting materials are normally of defined chemical
properties and structure. - Wirkstoff-Ausgangsmaterial |
|
| Aseptic | ||
|
|
An environment which is free from pathogenic microorganisms. - steril |
|
| Batch [1] | ||
|
|
means a specific quantity of drug substance or other material that is
intended to have uniform character and quality, within specified limits,
and is produced according to a single manufacturing order during the same
cycle of manufacture. |
|
| Batch (or Lot) [2] | ||
|
|
A specific quantity of material produced in a process or series of processes
so that its expected to be homogeneous within specified limits. In the
case of continuous production a batch may correspond to a defined fraction
of the production, characterised by its intended homogeneity. The batch
size may be defined either by a fixed quantity or the amount produced
in a fixed time interval. |
|
| Batch Number (or Lot Number) [2] | ||
|
|
A distinctive combination of numbers and/or letters which specifically
identify a batch or lot and from which the production history can be determined. |
|
| Batch Number (or Lot Number) [1] | ||
|
|
A unique combination of numbers and/or letters which specifically identify
a batch or lot and from which the production and distribution history
can be determined. |
|
| Batch Record | ||
|
|
Documentation that provides the history of a batch from the raw material
stage to completion of the lot/batch. |
|
| Biological Active Pharmaceutical Ingredient [2] | ||
|
|
means a material originating from a biological manufacturing process
intended to be used in the manufacture of a medicinal product which provides
the therapeutic activity of a medicinal product or other direct effect
in the diagnosis of a disease. |
|
| Biologic Product | ||
|
|
Any virus, therapeutic serum, toxin, antitoxin, or analogous product
applicable to the prevention., treatment, or cure of diseases or conditions
of human beings. |
|
| Blending (Mixing) | ||
|
|
Intermingling different conforming grades into a homogeneous lot. |
|
| Bulk Pharmaceuticals (BPs) | ||
|
|
Materials (both pharmacologically active and inactive) which are intended
for use as a component of a drug or biological product. These include
materials manufactured by processes such as: (1) chemical synthesis; (2)
fermentation; (3) recombinant DNA or other biotechnology methods; (4)
isolation/recovery from natural sources, or (5) any combination of these
processes. |
|
| Bulk Pharmaceutical Chemical (BPC) | ||
|
|
means any substance produced by chemical synthesis, fermentation, recombinant
DNA processes or recovery from natural materials which is intended for
use as a component in a drug product or a substance which is repackaged
or labeled for drug use.
|
|
| Bulk Pharmaceutical Excipient (BPE) | ||
|
|
||
| Calibration [2] | ||
|
|
The demonstration that a particular instrument or device produces results
within specified limits by comparison with those produced by a traceable
standard over an appropriate range of measurements. |
|
| Certificate of Analysis | ||
|
|
A document relating specially to the results of testing a representative
sample drawn from the material to be delivered. |
|
| Chemical Reaction | ||
|
|
A process that involves a chemical transformation of a starting material
or intermediate to form a new compound (e.g., bond formation, oxidation,
reduction) |
|
| Clean Area | ||
|
|
An area with defined environmental control of particulate and microbial
contamination, constructed and used in such a way as to reduce the introduction,
generation and retention of contaminants in the area. |
|
| Cleaning Agent | ||
|
|
Any material used to clean process equipment , utensils, and storage
vessels. These may include soaps, detergents, surfactants, alkalis, acids,
or other materials, such as organic solvents, if the solvent is specially
used for cleaning and is not a solvent used in the next processing step. |
|
| Commingling | ||
|
|
The blending of trace carryover material from one grade of an excipient
with another usually due to a continuous process. |
|
| Component [1] | ||
|
|
means any ingredient intended for use in the manufacture of a drug product,
including those that may not appear in such drug product. |
|
| Computer System [2] | ||
|
|
A group of hardware components and associated software, designed and
assembled to perform a specific function or group of functions. |
|
| Computerized System [2] | ||
|
|
A process or operation integrated with a computer system. |
|
| Concurrent Validation | ||
|
|
A subset of prospective validation in which API batches are released
for distribution, based on extensive testing, before completion of process
validation. Once data from additional batches produced under replicated
conditions show uniformity, the process may be considered validated. |
|
| Containment | ||
|
|
Achieving a level of control over a raw material, intermediate, or API
that provides proper protection of these materials from external contamination
and cross-contamination. |
|
| Contaminant | ||
|
|
An impurity not intended to be present in an excipient that may be introduced
through such things as poor cleaning, processing, lack of appropriate
environmental and personnel controls during the manufacturing process. |
|
| Contamination [2] | ||
|
|
The undesired introduction of impurities of a chemical or microbiological
nature, or of foreign matter, into or onto a raw material, intermediate,
or API during production, sampling, packaging or repackaging, storage
or transport. |
|
| Continuous Production | ||
|
|
A process in which a material is continuously produced in a step or series
of steps. In a continuous process, the batches of raw materials and the
process parameters can be statistically, but not absolutely, correlated
to the material produced in a given period of time. |
|
| Continuous Production [2] | ||
|
|
||
| Critical [2] | ||
|
|
A material, process step or process condition, test requirement or any
other relevant parameter is considered to be critical when non-compliance
with predetermined criteria directly influences the quality attributes
of the API in a detrimental manner. |
|
| Critical Instrument | ||
|
|
means any instrument associated with the manufacturing, storage, or testing
of material which can directly impact the attributes and/or quality of
the material. |
|
| Critical Process | ||
|
|
A manufacturing process step which may cause variation in quality attributes. |
|
| Critical Process Parameters | ||
|
|
Process parameter that must be controlled within established operating
ranges to ensure that the API or intermediate will meet specifications
for quality and purity. |
|
| Critical Process Steps | ||
|
|
Production steps that must be controlled to ensure that the intermediate
or API will meet specifications for identity, strength, quality and purity |
|
| Cross-Contamination [2] | ||
|
|
Contamination of a material or product with another material or product. |
|
| Development Report | ||
|
|
means a report that summarizes the major stages of the drug substance
development from early stages through largescale manufacturing. |
|
| Drug | ||
|
|
As defined as section 201 (g)(1) of the act means (a) articles that are
, in the official United States Pharmacopeia, official Homeopathic Pharmacopeia
of the United States, or official National formulary, or any supplement
to them; (b) articles intended for use in the diagnosis, cure, mitigation,
treatment, or prevention of disease in humans or other animals; and articles
(other than food) intended to affect the structure or any function of
the body of humans or other animals. |
|
| Drug Master File (DMF) | ||
|
|
Detailed information concerning a specific facility, process or product
submitted to the United States Food and Drug Administration intended for
incorporation by reference into a new drug application, abbreviated new
drug application, or investigational a new drug application. |
|
| Drug Product [1] | ||
|
|
A finished dosage form, for example, a tablet, capsule or solution, that
contains an active pharmaceutical ingredient, generally, but not necessarily,
in association with inactive ingredients. The term also includes a finished
dosage form that does not contain an API but is intended to be used as
a placebo. |
|
| Drug (Medicinal) Product [2] | ||
|
|
The dosage form in the final immediate packaging intended for marketing. |
|
| Drug Substance [2] | ||
|
|
or Active Pharmaceutical Ingredient (API) |
|
| Equipment suitability | ||
|
|
Establishing confidence that process equipment and ancillary systems
can consistently operate within established limits and tolerances. |
|
| Excipient | ||
|
|
Excipients are any substances other than the active drug or product which
have been appropriately evaluated for safety and are included in a drug
delivery system to either aid the processing of the drug delivery system
during its manufacture, protect, support or enhance stability, bioavailability,
or patient acceptability, assist in product identification, or enhance
any other attribute of the overall safety and effectiveness of the drug
delivery system during storage or use. |
|
| Expected Yield [2] | ||
|
|
The quantity of material or the percentage yield anticipated at any appropriate
phase of production based on the historical data of process. |
|
| Expiry/Expiration Date [2] | ||
|
|
The date placed on the container/labels of an API designating the time
during which the API is expected to remain within established shelf- life
specifications if stored under defined con-ditions, and after which it
should not be used. |
|
| Extraneous Substance | ||
|
|
An impurity arising from any source extraneous to the manufacturing process. |
|
| Fiber [1] | ||
|
|
means any particulate contaminant with a length at least three times
greater than its width. |
|
| Final Intermediate | ||
|
|
The last compound from which the Active Ingredient is produced. In the
case of organic compounds this means a change in at least one covalent
bond whilst for inorganic compounds this may mean a change in an ionic
bond. The final intermediate is thus a starting material for the process
step which produces the Active Ingredient. |
|
| Final Production Stages | ||
|
|
The purification and subsequent process steps to give the pure Active
Ingredient and, if necessary, the further steps to produce the final Active
Ingredient. |
|
| Finished Dosage Form (Drug Product) | ||
|
|
A finished pharmaceutical product containing excipients and the active
and the active drug substance which has been prepared for consumer applications. |
|
| Finished Product | ||
|
|
Any pharmaceutical product which has undergone all stages of production,
including packaging and labeling. |
|
| Finished Process Materials | ||
|
|
Any material which has undergone all stages of production and is released from quality control. |
|
| Gang-printed labeling [1] | ||
|
|
Means labeling derived from a sheet of material on which more than one item of labeling is printed. |
|
| GMPs | ||
|
|
Good Manufacturing Practices. |
|
| Homogeneous Material | ||
|
|
Material of uniform consistency and composition through a batch. |
|
| Inactive Ingredient [1] | ||
|
|
Any component other than an active ingredient. |
|
| In-Process Control (also called Process Control) | ||
|
|
Checks performed during production in order to monitor and if necessary
to adjust the process and/or to ensure that the intermediate or API conforms
to its specification. |
|
| In-Process Control [2] | ||
|
|
Checks performed during production in order to monitor and if necessary
to adjust the process to ensure that the API conforms to its specification.
The control of the environment or equipment may also be regarded as a
part of in-process control. |
|
| In-Process Material [1] | ||
|
|
means any material fabricated, compounded, blended, or derived by chemical
reaction that is produced for, and used in, the preparation of the drug
product. |
|
| In-Process Testing | ||
|
|
Monitoring checks performed during production to ensure that the product
conforms to its specifications. |
|
| Intermediate [2] | ||
|
|
A material produced during steps of the processing of an API which must
undergo further molecular change purification before it becomes an API. |
|
| Intermediate | ||
|
|
A material produced during a manufacturing process that must undergo
further molecular change or processing before it becomes an API or a biological
API. Types of intermediates include: Final Intermediate means the last intermediate isolated and controlled
during the manufacturing process, before the final step that creates
the crude API In-Situ Intermediate means an intermediate that is not isolated, however,
requires adequate in-process controls before proceeding to the next
step in the manufacturing process. Key Intermediate means an intermediate in which at least one essential
molecular characteristic, usually involving the proper stereochemical
configuration required for structure or pharmacological/physiological
activity, is first introduced into the molecular structure. Pivotal Intermediate means an intermediate that may be prepared by more than one manufacturing
process to provide material of suitable quality for use in the production
of an API. |
|
| Intermediate Product | ||
|
|
Material which must undergo further manufacturing steps before it becomes
a bulk product |
|
| Lot [1] | ||
|
|
means a batch, or a specific identified portion of a batch, having uniform
character and quality within specified limits; or, in the case of a material
produced by continuous process, a specific identified amount or the quantity
produced in a unit of time or quantity in a manner that assures uniform
character and quality within specified limits. |
|
| Lot [2] | ||
|
|
||
| Lot Number (Control Number or Batch Number) [1] | ||
|
|
means any distinctive combination of letters, numbers, or symbols or
any combination of them, from which the complete history of the manufacture,
processing, packing, holding, and distribution of a batch or lot of drug
substance or other material can be determined. |
|
| Manufacture | ||
|
|
All operations of purchase of materials, production, quality control,
release, storage, and distribution of APIs and the related controls. |
|
| Manufacture [2] | ||
|
|
All operations of receipt of materials, production, packaging, repackaging,
labelling, relabelling, quality control, release, storage and distribution
of APIs and the related controls. |
|
| Manufacture [2] | ||
|
|
All operations of purchase and receipt of materials, production, packaging,
labelling, quality control, release, storage and distribution of APIs
and the related controls. |
|
| Manufacture, Processing, Packing or Holding [1] | ||
|
|
includes packaging and labeling operations, testing, and quality control
of drug products. |
|
| Manufacturer | ||
|
|
The company which performs the final production steps and release of
the product. |
|
| Manufacturing Process | ||
|
|
All steps neccessary to produce a finished product from raw materials. |
|
| Master Formula (Master Formula Record) | ||
|
|
Documentation describing the manufacture of the excipient from raw material
to completion of the lot/batch. |
|
| Material [2] | ||
|
|
A general term used to denote raw materials, starting materials, intermediates,
APIs and packaging materials. |
|
| medicated feed [1] | ||
|
|
means any Type B or Type C medicated feed as defined in § 558.3
of this chapter. The feed contains one ore more drugs as defined in section
201(g) of the act. The manufacture of medicated feedis subject to the
requirements of part 225 of this chapter. |
|
| medicated premix [1] | ||
|
|
means a Type A medicated article as defined in § 558.3 of this chapter.
The article contains one ore more drugs as defined in section 201(g) of
the act. The manufacture of medicated premixes is subject to the requirements
of part 226 of this chapter |
|
| Methods Validation | ||
|
|
The documented successful evaluation of an analytical method that provides
a high level of assurance that the method will consistently yield reliable
and accurate results, within previously established specifications. |
|
| Model Product | ||
|
|
A product which simulates a group of like products. |
|
| Mother Liquor [2] | ||
|
|
The residual liquid which remains after the crystallisation or isolation
processes. A mother liquor may contain unrecovered products (i.e., unreacted
starting materials, intermediates, levels of the API and/or impurities).
It may be used for further processing. |
|
| Mother Liquor [2] | ||
|
|
The residual saturated liquid which remains after the crystallisation
of a liquid. A mother liquor may contain unrecovered products (i.e., unreacted
starting materials, intermediates, trace levels of the API and/or impurities). |
|
| New Active Substance [2] | ||
|
|
The designated therapeutic moiety which has not been a previously registered
in a member state (also referred to as a new molecular entity or new chemical
entity). It may be a complex, simple ester, or salt of a previously approved
substance. |
|
| New Chemical Entity | ||
|
|
A chemical that has not been adequately characterized in the literature
regarding its physical and chemical properties. |
|
| New Molecular Entity | ||
|
|
The designed therapeutic moiety (API) in a dosage form that has not been
approved for marketing in the United States (also referred to as a new
chemical entity or new drug substance). It may be a complex, simple ester,
or salt of a previously approved API. |
|
| Nonconforming Material | ||
|
|
Any material that does not meet manufacturer’s specifications
or applicable GMPs. |
|
| Non-Fiber-Releasing Filter [1] | ||
|
|
means any filter, which after any appropriate pretreatment such as washing
and flushing, will not release fibers into the component or drug product
that is being filtered. All filters composed of asbestos are deemed to
be fiber-releasing filters. |
|
| Optional Process Steps draft definition [2] | ||
|
|
Optional process steps are steps that may be run based on a decision.
Such an optional step should be a well defined written process. There
should be defined criteria for the decision as to whether or not optional
steps will be used. |
|
| Packaging Material [2] | ||
|
|
Any Material used to protect an Active Ingredient during storage and
transport but excluding labels. |
|
| Packaging Material [2] | ||
|
|
Any Material intended to protect an intermediate or API during storage
and transport. |
|
| Percentage of Theoretical Yield [1] | ||
|
|
means the ratio of the actual yield (at any appropriate phase of production
of a particular drug substance or intermediate) to the theoretical yield
(at the same phase), stated as a percentage. |
|
| Physical Manipulation [2] | ||
|
|
A process other than chemical reaction that may change the purity or
the physical properties of the material, including but not limited to
crystallisation, recrystallisation, gel filtration, chromatography, milling,
drying or blending. |
|
| Pilot Scale | ||
|
|
The manufacture of an API on a reduced scale by processes representative
of and simulating those to be applied on a larger commercial manufacturing
scale. |
|
| Polymorphism | ||
|
|
The occurence of different crystalline forms of the same API. |
|
| Potential Impurity | ||
|
|
An impurity that, from theoretical consider-ations, may arise from or
during manufacture. It may or may not actually appear in the API. |
|
| Primary Reference Standard [2] | ||
|
|
A substance that has been shown by an extensive set of analytical tests,
to be authentic material of high purity. This standard may be obtained
from a recognised source or may be prepared by independent synthesis or
by further purification of existing production material. |
|
| Procedures [2] | ||
|
|
A written description of the operations to be carried out, the precautions
to be taken and measures to be applied directly or undirectly related
to be manufacture of an intermediate or API. |
|
| Procedures [2] | ||
|
|
Description of the operations to be carried out, the precautions to be
taken, and measures to be applied directly or undirectly related to the
manufacture of an API. |
|
| Process Aid [2] | ||
|
|
Materials used as an aid in the manufacture of an API which themselves
do not participate in the chemical or biological reaction. |
|
| Process Aid [2] | ||
|
|
Materials, excludig solvents, used as an aid in the manufacture of an
intermediate or API which themselves do not participate in the chemical
or biological reaction (e.g. filter aid, activated carbon, etc.). |
|
| Process Control [2] | ||
|
|
Also called In-Process Control. |
|
| Process Validation [2] | ||
|
|
Establishing documented evidence that provides a high degree of assurance
that a specific process will consistently produce a product meeting its
predetermined specifications and quality characteristics. |
|
| Processing Instructions | ||
|
|
The manufacturing procedures set forth in the Master Formula. |
|
| Production [2] | ||
|
|
All operation involved in the preparation of an API, from receipt of
materials, trough processing and packaging, to its completion as a finished
API. |
|
| Prospective Validation | ||
|
|
Establishing documented evidence that a system does what it purports
to do prior to the commercial distribution of a new API or an existing
API made by a new or modified process. |
|
| Purification | ||
|
|
The process of removing impurities from a substance. |
|
| Purification Procedure | ||
|
|
A process, such as crystallization, distillation, or chromatography,
intended to improve the purity of an intermediate, API, or biologic API. |
|
| Qualification [2] | ||
|
|
Action of proving and documenting that equipment or ancillary systems
are properly installed, work correctly, and actually lead to the expected
results. Qualification is part of validation, but the individual qualification
steps alone do not constitute process validation. |
|
| Qualification [2] | ||
|
|
Action of proving that any equipment works correctly and actually leads
to the expected results. The word “validation“ is sometimes
widened to incorporate to the concept of qualification. |
|
| Quality | ||
|
|
The totality of features and characteristics of a product that bear on
its ability to satisfy stated or implied needs. |
|
| Quality Assurance (QA) [2] | ||
|
|
The sum total of the organised arrangements made with the object of ensuring
that all APIs are of the quality required for their intended use. |
|
| Quality Attribute | ||
|
|
Any product characteristic which may reflect quality, or may affect safety
or efficacy of the product during its expected shelf life. |
|
| Quality Control (QC) [2] | ||
|
|
Checking or testing, that specifications are met and quality systems
are maintained. |
|
| Quality Control Instruments | ||
|
|
Measurement instruments used to monitor the manufacturing process, in-process
controls and the finished excipient products for final quality control
approval. |
|
| Quality Control Unit [1] | ||
|
|
Any person or organizational element designated by the firm to be responsible
for the duties relating to quality control. |
|
| Quality Control Unit [2] | ||
|
|
An organisational unit with defined responsibilities and authority for
controlling, through checking or testing, that specifications are met
and quality systems are maintained. |
|
| Quality Unit(s) [2] | ||
|
|
An organizational unit independent of production which fulfills both
Quality Assurance and Quality Control responsibilities. This may be in
the form of separate QA and QC units, a single individual (or group),
depending upon the size and structure of the organization. |
|
| Quarantine [2] | ||
|
|
The status of materials isolated physically or by other effective means
pending a decision on their subsequent use. |
|
| Quarantine [2] | ||
|
|
The status of materials isolated physically or by other effective means
pending a decision on their subsequent approval or rejection. |
|
| Range for Critical Process Parameters | ||
|
|
The range for each critical process parameter generally developed on research or pilot scale batches that encompasses values that are capable of producing intermediates and APIs with acceptable quality attributes. |
|
| Raw Material [2] | ||
|
|
Any ingredient intended for use in the production of APIs. These may
include starting materials, process aids, solvents and reagents. |
|
| Raw Material [2] | ||
|
|
Any ingredient intended for use in the production of APIs. These may
include starting materials, process aids, and solvents. |
|
| Reagent [2] | ||
|
|
A substance, other than a starting material or solvent, that is used
in the manufacture of an API or intermediate. |
|
| Recovery [2] | ||
|
|
Any treatment of materials by a process intended to make them suitable
for further use. |
|
| Reevalation Date | ||
|
|
means the date prior to which the drug substance meets all specifications
and beyond which the drug substance shall not be used without prior adequate
re-examination. This date shall be based on the stability of the drug
substance or experience with the drug substance. |
|
| Reference Standard | ||
|
|
An API of high purity, specifically prepared by independent synthesis
or by further purification of existing production material |
|
| Rejected Material | ||
|
|
means any material or item which has been determined to be unacceptable
for the specified use. |
|
| Repeating a Chemical Reaction | ||
|
|
Adding fresh reagents or solvents to unreacted or base material and repeating
a chemical reaction from its beginning. This excludes those situations
where a chemical reaction is continued or extended in the same vessel
with the addition of more solvent, to ensure completion of a reaction
or increase the yield and/or purity of the API (e.g., continuation of
a hydrogenation step). |
|
| Representative Sample [1] | ||
|
|
means a sample that consists of a number of units that are drawn based
on rational criteria such as random sampling and intended to assure that
the sample accurately portrays the material being sampled. |
|
| Reprocess | ||
|
|
means introducing previously processed material, which did not conform
to standards or specifications, back into the process and repeating steps
which are already part of the normal manufacturing process (e.g. to dry
again under the same process/conditions, etc.). - Wiederholung validierter Verfahrensschritte - Reprocessing |
|
| Reprocessing [2] | ||
|
|
Repeating a crystallization step or other appropriate chemical or physical
manipulation steps such as distillation, filtration, chromatography, milling,
etc. according to procedures used to manufacture the original batch. Continuation
of a chemical reaction after an inprocess control test shows the reaction
to be incomplete is considered to be part of the normal process, and not
reprocessing. - wiederaufarbeiten |
|
| Reprocessing [2] | ||
|
|
Introducing an intermediate or API that does not conform to standards
or specifications, back into the process and repeating step(s) that are
part of the established manufacturing process, so that its quality may
be made acceptable (e.g., recrystallizing using the same solvent). - wiederaufarbeiten |
|
| Reserve (Retained) Sample | ||
|
|
A representative sample of sufficient quality and quantity needed of the final excipient batch to perform quality control analyses twice. |
|
| Responsible Individual | ||
|
|
means that person with the authority to initiate appropriate actions. - verantwortliche Person |
|
| Retest Date [2] | ||
|
|
The date when the API should be re-examined to ensure that is still suitable for use. |
|
| Retest Date [2] | ||
|
|
The date when samples of the API should be re-examined that material
is still suitable for use. - Neuer Prüftermin |
|
| Retest Period [2] | ||
|
|
The period of time during which the API can be considered to remain within
specifications and therefore acceptable for use in the manufacture of
a given drug product, provided that it has been stored under defined conditions.
After this period, the batch should be retested for compliance with specifications
before use. - Freigabezeitraum |
|
| Retrospektive Validation | ||
|
|
Establishing documented evidences that a sys-tem does what it purports
to do based on a re-view and analysis of historic information. It is normally
conducted on an API already being commercially distributed and is based
on accu-mulated production, testing, and control data. - retrospektive Validierung |
|
| Returned Products | ||
|
|
Finished products sent back to the manufacturer. - zurückgeschichte Produkte |
|
| Rework | ||
|
|
means introducing previously processed material, which did not conform
to standards or specifications, to processing steps which are different
than the normal process (e.g. to recrystallize with a new solvent, etc.) - Überarbeitung mit nicht validierten Prozeßschritten |
|
| Reworking [2] | ||
|
|
Subjecting an intermediate or API that does not conform to standards
or specifications, to one or more processing steps that are different
from the established manufacturing process so that its quality may be
made acceptable (e.g., recrystallizing with a different solvent). - Überarbeitung mit nicht validierten Prozeßschritten |
|
| Secondary Reference Standard [2] | ||
|
|
A substance of established quality and purity, as shown by comparison
to a primary reference standard, used as a reference standard for routine
laboratory analysis. - Sekundärer Referenz-Standard |
|
| Separate Facility | ||
|
|
means a facility that provides for a very high degree of containment
of materials and prevention of contamination. This may be accomplished
by several means such as, separate buildings, a building within a building,
or closed systems within a building. - separate Einrichtung |
|
| Shelf Life | ||
|
|
The length of time during which the excipient exhibits
stability.
- Stabilitätsdauer |
|
| Signed [2] | ||
|
|
The record of who performed a particular action or review. This record
may be initials, full handwritten signature, or authenticated and secure
electronic signature. - Abzeichnung / Kennzeichnung |
|
| Significant Processing Step | ||
|
|
Processing steps that are required to produce an excipient that meets
the established physical criteria. - bedeutender Verfahrensschritt |
|
| Solvent [2] | ||
|
|
Any liquid used as a vehicle for the preparation of solutions or suspensions
in the synthesis of an API or intermediate. - Lösungsmittel |
|
| Solvent [2] | ||
|
|
An inorganic or organic liquid used as a vehicle for the preparation
of solutions or suspensions in the manufacture of an intermediate or API. |
|
| Specification [2] | ||
|
|
A list of tests, references to analytical procedures, and appropriate
acceptance criteria that are numerical limits, ranges, or other criteria
for the test described. It establishes the set of criteria to which an
intermediate or API should conform to be considered acceptable for the
intended use. „Conformance to Specifications“ means that
the intermediate or API, when tested according to the listed analytical
procedures, will meet the listed acceptance criteria. |
|
| Stability | ||
|
|
The continued conformance of the excipient to its specification. - Stabilität |
|
| Standard Operating Procedures (SOPs) | ||
|
|
A written authorized procedure which gives instructions for performing
operations. - Allgemeine Arbeitsanweisung |
|
| Starting Material [2] | ||
|
|
A material used in the synthesis of an API, which is incorporated as
an element into the structure of an intermediate and/or of the API. Starting
materials are normally commercially available and of defined chemical
and physical properties and structure. - Ausgangsmaterial |
|
| Strength [1] | ||
|
|
a) The concentration of the drug substance (for example, weight/weight,
weight/volume, or unit dose/volume basis) and/or b) The potency, that is, the therapeutic activity of the drug product
as indicated by appropriate laboratory tests or by adequately developed
and controlled clinical data (expressed, for example, in terms of units
by reference to a standard). - Wirkstärke |
|
| Theoretical Yield [1] | ||
|
|
The quantity that would be produced at any appropriate phase of manufacture,
processing, or packing of a particular API or intermediate, based upon
the quantity of components to be used, in the absence of any loss or error
in actual production. |
|
| Toxic Impurity | ||
|
|
Impurities having significant undesirable biological activity. - giftige Verunreinigung |
|
| Unidentified Impurity | ||
|
|
An impurity that is defined solely by qualitative properties (e.g., chromatograpfic
retention time). - nichtidentifizierte Verunreinigung |
|
| Validation [2] | ||
|
|
A documented program that provides a high degree of assurance that a
specific process, method, or system will consistently produce a result
meeting pre-determined acceptance criteria. |
|
| Validation [2] | ||
|
|
Action of proving, in accordance with the principles of GMP, that any
procedure, process, equipment, material, activity or system actually leads
to the expected results. |
|
| Validation Protocol [2] | ||
|
|
A written plan stating how validation will be conducted. For example,
the protocol for a manufacturing process identifies processing equipment,
critical process parameters/operating ranges, product characteristics
sampling and test data to be collected, number of validation runs, and
acceptable test results. - Validierungsplan |
|
| Vendor | ||
|
|
An organization contracted to supply a material or perform a service. - Lieferant |
|
| Working Standard | ||
|
|
An API or biological API of high quality and purity, used as an analytical
reference substance for routine laboratory analysis. The analytical testing
needed to document the suitability of the working standard should generally
be more extensive than that used for the API, and it is compared with
a primary reference standard. - Arbeits-Substanz |
|